Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
June 2014

The Downside of Testosterone
Prescribed testosterone can be an effective medical intervention in selected cases of hypogonadism in men, but its use as a rejuvenator for all men appears unwarranted.

Agitation in Alzheimer Disease: a Role for an SSRI?
Citalopram (Celexa and others) seems to decrease agitation in patients with Alzheimer disease, but it may have adverse cardiac effects.

Renal Failure Risk with Lithium
The risk to kidney function from long-term treatment with lithium may be compounded by increasing patient age.

In Brief
GlaxoSmithKline Recalls Batches of Paroxetine for Possible Contamination; Marijuana Use Associated with Structural Brain Changes

Maintenance Antipsychotic Strategy: Highs and Lows
After remission is achieved on antipsychotic therapy after a first episode of schizophrenia, reducing or discontinuing the antipsychotic may have long-term benefits over standard-dose maintenance treatment.

Agitation in Alzheimer Disease: a Role for an SSRI?

June 2014

As we age, our risk of developing dementia rises. In the United States, only about 10% of 65-year-olds are likely to develop dementia, but roughly 30% of 85-year-olds will.1 The most common cause of dementia is Alzheimer disease.

BTP frequently notes that agitation in patients…

To view the rest of this article, please: